Free Trial

Cardiff Oncology (CRDF) Short Interest Ratio & Short Volume

Cardiff Oncology logo
$3.87 -0.43 (-10.00%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$3.94 +0.06 (+1.68%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology Short Interest Data

Cardiff Oncology (CRDF) has a short interest of 17.63 million shares, representing 37.39% of the float (the number of shares available for trading by the public). This marks a 0.63% increase in short interest from the previous month. The short interest ratio (days to cover) is 15.3, indicating that it would take 15.3 days of the average trading volume of 1.16 million shares to cover all short positions.

Current Short Interest
17,630,000 shares
Previous Short Interest
17,520,000 shares
Change Vs. Previous Month
+0.63%
Dollar Volume Sold Short
$58.88 million
Short Interest Ratio
15.3 Days to Cover
Last Record Date
May 31, 2025
Outstanding Shares
66,526,000 shares
Short Percent of Float
37.39%
Today's Trading Volume
1,558,687 shares
Average Trading Volume
1,161,595 shares
Today's Volume Vs. Average
134%
Short Selling Cardiff Oncology?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Cardiff Oncology and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CRDF Short Interest Over Time

CRDF Days to Cover Over Time

CRDF Percentage of Float Shorted Over Time

Cardiff Oncology Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/31/202517,630,000 shares $58.88 million +0.6%37.4%15.3 $3.34
5/15/202517,520,000 shares $48.18 million +0.2%37.2%15 $2.75
4/30/202517,480,000 shares $47.90 million +0.8%N/A14.7 $2.74
4/15/202517,340,000 shares $50.98 million +17.1%36.8%14.3 $2.94
3/31/202514,810,000 shares $46.50 million +11.0%31.4%12.7 $3.14
3/15/202513,340,000 shares $53.36 million +17.2%28.3%11.5 $4.00
2/28/202511,380,000 shares $48.25 million +5.0%24.1%5.4 $4.24
2/15/202510,840,000 shares $46.50 million +3.7%23.0%5.4 $4.29
1/31/202510,450,000 shares $42.11 million +10.2%N/A5 $4.03
1/15/20259,480,000 shares $32.61 million -0.3%N/A4.6 $3.44
12/31/20249,510,000 shares $41.27 million -4.4%N/A4.8 $4.34
12/15/20249,950,000 shares $39.00 million +21.6%N/A5.2 $3.92
11/30/20248,180,000 shares $21.35 million +6.0%N/A5.5 $2.61
11/15/20247,720,000 shares $19.92 million -4.3%N/A10.9 $2.58
10/31/20248,070,000 shares $25.18 million +10.3%N/A12.2 $3.12
10/15/20247,320,000 shares $19.54 million +7.2%N/A14.8 $2.67
9/30/20246,830,000 shares $18.24 million -1.0%N/A14.5 $2.67
9/15/20246,900,000 shares $18.70 million No ChangeN/A12.4 $2.71
8/31/20246,900,000 shares $15.94 million +2.7%N/A12.7 $2.31
8/15/20246,720,000 shares $16.06 million +16.3%N/A11.7 $2.39
7/31/20245,780,000 shares $13.53 million +12.9%N/A9.7 $2.34
7/15/20245,120,000 shares $12.85 million +21.3%N/A7.7 $2.51
6/30/20244,220,000 shares $9.37 million +4.5%N/A5.8 $2.22
6/15/20244,040,000 shares $10.91 million -9.4%N/A5.4 $2.70
5/31/20244,460,000 shares $14.18 million -3.5%N/A4.7 $3.18
5/15/20244,620,000 shares $16.49 million +4.5%N/A2.4 $3.57
4/30/20244,420,000 shares $19.27 million +10.8%N/A2.3 $4.36
4/15/20243,990,000 shares $21.07 million +17.0%N/A2.2 $5.28
3/31/20243,410,000 shares $18.21 million +21.4%N/A2 $5.34
3/15/20242,810,000 shares $14.13 million +144.4%N/A1.8 $5.03
2/29/20241,150,000 shares $2.03 million -3.4%N/A0.9 $1.77
2/15/20241,190,000 shares $2.08 million -7.8%N/A7.6 $1.75
1/31/20241,290,000 shares $2.01 million +13.2%N/A7.5 $1.56
1/15/20241,140,000 shares $1.93 million -13.6%N/A6.5 $1.69
12/31/20231,320,000 shares $1.95 million -2.2%N/A6.4 $1.48
12/15/20231,350,000 shares $1.89 million -6.9%N/A2 $1.40
11/30/20231,450,000 shares $1.78 million -9.4%N/A2.1 $1.23
11/15/20231,600,000 shares $1.94 million -1.8%N/A2.3 $1.21
10/31/20231,630,000 shares $1.74 million +6.5%N/A2.2 $1.07
10/15/20231,530,000 shares $1.70 million -24.6%N/A1.4 $1.11
Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)

Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.

Click here to see why Tesla's about to prove everyone wrong... again.
9/30/20232,030,000 shares $2.82 million +201.6%N/A1.9 $1.39
9/15/2023673,000 shares $1.16 million +25.4%N/A1.1 $1.73
8/31/2023536,500 shares $987.16 thousand -19.5%N/A0.9 $1.84
8/15/2023666,400 shares $1.33 million +28.7%N/A1.2 $2.00
7/31/2023517,700 shares $916.33 thousand +5.0%N/A1 $1.77
7/15/2023492,900 shares $694.99 thousand -8.2%N/A3.3 $1.41
6/30/2023537,000 shares $789.39 thousand +1.0%N/A3.5 $1.47
6/15/2023531,600 shares $845.24 thousand -1.7%N/A3.4 $1.59
5/31/2023541,000 shares $871.01 thousand -0.2%N/A2.9 $1.61
5/15/2023542,300 shares $949.03 thousand -12.1%N/A2.7 $1.75
4/30/2023616,900 shares $1.07 million -2.4%N/A2.9 $1.74
4/15/2023632,000 shares $941.68 thousand +1.2%N/A3 $1.49
3/31/2023624,300 shares $1.03 million -7.3%N/A2.6 $1.65
3/15/2023673,600 shares $1.16 million -1.6%N/A2.6 $1.72
2/28/2023684,400 shares $1.18 million -14.6%N/A2.9 $1.73
2/15/2023801,300 shares $1.50 million -11.6%N/A3.3 $1.87
1/31/2023905,900 shares $1.62 million -9.4%N/A3.6 $1.79
1/15/20231,000,000 shares $1.53 million -8.3%N/A3.9 $1.53
12/30/20221,090,000 shares $1.53 million -5.2%N/A4.6 $1.40
12/15/20221,150,000 shares $1.61 million -2.5%N/A4.4 $1.40
11/30/20221,180,000 shares $1.88 million -1.7%N/A2.3 $1.59
11/15/20221,200,000 shares $1.61 million -7.7%N/A2.2 $1.34
10/31/20221,300,000 shares $2.12 million -19.8%N/A2.2 $1.63
10/15/20221,620,000 shares $2.49 million -10.0%N/A2.6 $1.54
9/30/20221,800,000 shares $2.77 million -18.2%N/A2.7 $1.54
9/15/20222,200,000 shares $3.67 million +9.5%N/A2.5 $1.67
8/31/20222,010,000 shares $5.41 million -7.4%N/A2.2 $2.69
8/15/20222,170,000 shares $6.55 million +4.3%N/A2.3 $3.02
7/31/20222,080,000 shares $4.60 million -8.4%N/A2.2 $2.21
7/15/20222,270,000 shares $6.13 million -12.0%N/A2.2 $2.70
6/30/20222,580,000 shares $5.68 million -27.1%N/A2.5 $2.20
6/15/20223,540,000 shares $5.95 million +8.6%N/A3.8 $1.68
5/31/20223,260,000 shares $4.40 million -9.9%N/A4.3 $1.35
5/15/20223,620,000 shares $4.85 million +6.2%N/A5.4 $1.34
4/30/20223,410,000 shares $4.57 million +37.5%N/A4.9 $1.34
4/15/20222,480,000 shares $4.81 million -1.6%N/A3.4 $1.94
3/31/20222,520,000 shares $6.25 million +6.3%N/A3.1 $2.48
3/15/20222,370,000 shares $5.38 million +9.7%N/A2.8 $2.27
2/28/20222,160,000 shares $5.81 million -2.7%N/A2.6 $2.69
2/15/20222,220,000 shares $7.04 million -28.4%N/A2.8 $3.17
1/31/20223,100,000 shares $10.48 million -15.8%N/A2.8 $3.38
1/15/20223,680,000 shares $25.24 million +32.4%N/A3.8 $6.86
12/31/20212,780,000 shares $16.71 million +4.1%7.5%3.5 $6.01
12/15/20212,670,000 shares $15.41 million -9.5%7.2%3.3 $5.77
11/30/20212,950,000 shares $16.58 million +17.1%8.0%2.5 $5.62
11/15/20212,520,000 shares $13.66 million -7.4%N/A2 $5.42
10/29/20212,720,000 shares $15.97 million +1.5%7.3%2.8 $5.87
10/15/20212,680,000 shares $17.15 million +0.8%7.2%2.7 $6.40
9/30/20212,660,000 shares $17.72 million +3.5%7.1%2.5 $6.66
9/15/20212,570,000 shares $16.81 million -18.9%6.9%2.2 $6.54
Is Elon's empire crumbling? (Ad)

The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

Click here to see the Tesla shock that could blindside everyone.
8/31/20213,170,000 shares $23.24 million +11.6%8.5%2.9 $7.33
8/13/20212,840,000 shares $16.30 million +0.7%7.6%4.5 $5.74
7/30/20212,820,000 shares $15.00 million -2.4%8.1%4.3 $5.32
7/15/20212,890,000 shares $17.28 million -10.8%8.3%4.3 $5.98
6/30/20213,240,000 shares $21.55 million +24.6%9.3%4.9 $6.65
6/15/20212,600,000 shares $20.80 million -6.8%7.4%4.5 $8.00
5/28/20212,790,000 shares $23.44 million -10.0%8.0%4.1 $8.40
5/14/20213,100,000 shares $26.32 million +11.9%9.0%3.7 $8.49
4/30/20212,770,000 shares $26.34 million +8.6%8.1%2.8 $9.51
4/15/20212,550,000 shares $22.44 million -3.8%7.6%1.9 $8.80
3/31/20212,650,000 shares $24.12 million -51.0%7.9%1.5 $9.10
3/15/20215,410,000 shares $58.70 million +0.9%16.1%2.8 $10.85
2/26/20215,360,000 shares $52.26 million -9.9%15.9%2.8 $9.75
2/12/20215,950,000 shares $84.73 million -8.2%18.6%3.2 $14.24
1/29/20216,480,000 shares $75.17 million +10.8%20.1%3.7 $11.60
1/15/20215,850,000 shares $114.48 million No Change18.1%3.7 $19.57

CRDF Short Interest - Frequently Asked Questions

What is Cardiff Oncology's current short interest?

Short interest is the volume of Cardiff Oncology shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 17,630,000 shares of CRDF short. 37.39% of Cardiff Oncology's shares are currently sold short. Learn More on Cardiff Oncology's current short interest.

What is a good short interest ratio for Cardiff Oncology?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRDF shares currently have a short interest ratio of 15.0. Learn More on Cardiff Oncology's short interest ratio.

Which institutional investors are shorting Cardiff Oncology?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cardiff Oncology: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Cardiff Oncology?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 37.39% of Cardiff Oncology's floating shares are currently sold short.

Is Cardiff Oncology's short interest increasing or decreasing?

Cardiff Oncology saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 17,630,000 shares, an increase of 0.6% from the previous total of 17,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Cardiff Oncology's short interest compare to its competitors?

37.39% of Cardiff Oncology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cardiff Oncology: Pharvaris (4.14%), CorMedix Inc. (14.83%), Akebia Therapeutics, Inc. (9.58%), Oculis Holding AG (0.07%), LENZ Therapeutics, Inc. (14.12%), Praxis Precision Medicines, Inc. (9.88%), Zymeworks Inc. (10.61%), Chimerix, Inc. (4.27%), Avid Bioservices, Inc. (18.17%), Nuvation Bio Inc. (18.67%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

What does it mean to sell short Cardiff Oncology stock?

Short selling CRDF is an investing strategy that aims to generate trading profit from Cardiff Oncology as its price is falling. CRDF shares are trading down $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Cardiff Oncology?

A short squeeze for Cardiff Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRDF, which in turn drives the price of the stock up even further.

How often is Cardiff Oncology's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRDF, twice per month. The most recent reporting period available is May, 31 2025.




This page (NASDAQ:CRDF) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners